AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23451840 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counselling for high-risk families
Number of subjects: 358
Study 23451840 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance colonoscopy for moderate-risk families
Number of subjects: 358
Study 23451840 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of clinicians regarding familial risk and preventive measures
Number of subjects: 358
Study 23451906 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of S100B and NSE levels with clinical parameters
Number of subjects: 107
Study 23451906 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B
Number of subjects: 107
Study 23451906 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE
Number of subjects: 107
Study 23451906 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromarker panel with high-risk factors (nausea, vomiting, amnesia, loss of consciousness)
Number of subjects: 107
Study 23453092 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adjudication of AMI
Number of subjects: 1096
Study 23453092 — intervention group
Group type: COMPARATOR
Intervention: Local adjudication of AMI
Number of subjects: 1096
Study 23453106 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche hs-cTnT
Number of subjects: 842
Study 23453106 — intervention group
Group type: EXPERIMENTAL
Intervention: Beckman Coulter hs-cTnI
Number of subjects: 842
Study 23453106 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens hs-cTnI
Number of subjects: 842
Study 23453106 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn changes in UA
Number of subjects: 842
Study 23453513 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 1137
Study 23453513 — intervention group
Group type: COMPARATOR
Intervention: Sham injections plus verteporfin photodynamic therapy (ANCHOR)
Number of subjects: 1137
Study 23453513 — intervention group
Group type: COMPARATOR
Intervention: Sham injections alone (MARINA)
Number of subjects: 1137
Study 23454241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with steroid withdrawal and reduced cyclosporine A (target level 50-90 ng/ml)
Number of subjects: 23
Study 23454694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat (iv fat)
Number of subjects: 16
Study 23454694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat (po fat)
Number of subjects: 16
Study 23454694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous endotoxin (LPS)
Number of subjects: 16
Study 23454694 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glycerol
Number of subjects: 16
Study 23456389 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutation
Number of subjects: 148
Study 23456389 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS codon 13 mutations
Number of subjects: 148
Study 23456563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus FOLFOX6
Number of subjects: 41
Study 23456563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus reduced CapeOx (capecitabine 850 mg/m(2))
Number of subjects: 41
Study 23456745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (500 mg, 1000 mg)
Number of subjects: 6
Study 23457002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 520
Study 23457326 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (face-to-face or telephone) over 12 weeks
Number of subjects: 9
Study 23457326 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 9
Study 23457331 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic prostate cancer risk assessment offered to patients requesting a PSA test in intervention group practices.
Number of subjects: 1244
Study 23457331 — intervention group
Group type: COMPARATOR
Intervention: Current guidelines for handling patients requesting a PSA test in control group practices.
Number of subjects: 1244
Study 23457331 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experiences related to prostate cancer.
Number of subjects: 1244
Study 23457331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociocultural aspects of genetic risk assessment.
Number of subjects: 1244
Study 23457410 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18
Study 23457410 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 18
Study 23457473 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime/adenovirus boost malaria vaccine (3 monthly doses of DNA plasmids followed by a single boost with adenovirus vectors)
Number of subjects: 15
Study 23457473 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime/adenovirus boost malaria vaccine
Number of subjects: 15
Study 23458624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and intravenous omega-3 rich lipid emulsion (n-3FA)
Number of subjects: 0
Study 23459001 — intervention group
Group type: EXPERIMENTAL
Intervention: HHIP silencing
Number of subjects: 0
Study 23459001 — intervention group
Group type: COMPARATOR
Intervention: Control lung tissues
Number of subjects: 0
Study 23459494 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 18
Study 23459496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir-based therapy (including atazanavir, ritonavir, and emtricitabine-tenofovir)
Number of subjects: 35
Study 23459515 — intervention group
Group type: EXPERIMENTAL
Intervention: NKG2D/NKp30-independent bispecific antibody construct (CD30xCD16A)
Number of subjects: 0
Study 23459515 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 23459720 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized PCR assay with common calibrators and PCR master mix
Number of subjects: 40
Study 23460154 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO2R
Number of subjects: 20
Study 23460155 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsegmental WA%
Number of subjects: 983
Study 23460155 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema
Number of subjects: 983
Study 23460155 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in WA% between bronchial segments
Number of subjects: 983
Study 23461618 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive serum fibrosis indices calculated at the time of RFA
Number of subjects: 246
Study 23461618 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-platelet index (API) ≤7
Number of subjects: 246
Study 23461618 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP)
Number of subjects: 246
Study 23461618 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 246
Study 23461618 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bilirubin
Number of subjects: 246
Study 23463272 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23463422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular tissue plasminogen activator (rtPA)
Number of subjects: 24
Study 23463422 — intervention group
Group type: COMPARATOR
Intervention: Control (external ventricular drainage alone)
Number of subjects: 24
Study 23464850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with standardized pathological protocol (quality protocol)
Number of subjects: 150
Study 23465037 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg once weekly to 50 mg twice weekly
Number of subjects: 1853
Study 23465037 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 1853
Study 23465456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted wound closure (VAWCM)
Number of subjects: 28
Study 23466185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventana fenestrated stent grafts
Number of subjects: 15
Study 23466307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (15 mg/kg IV every 90 days until tumor progression or severe toxicity)
Number of subjects: 20
Study 23468161 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive bacterial culture after sonication in permanent implants
Number of subjects: 84
Study 23468161 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive bacterial culture after sonication in temporary implants
Number of subjects: 84
Study 23468161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial organisms identified
Number of subjects: 84
Study 23468307 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous omacetaxine 1.25 mg/m² twice daily days 1-14 every 28 days until hematologic response, then days 1-7 every 28 days as maintenance.
Number of subjects: 46
Study 23468538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular cooling after intra-arterial reperfusion therapy (IAT)
Number of subjects: 20
Study 23468548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenoses and occlusions
Number of subjects: 2187
Study 23468548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstenotic carotid plaques
Number of subjects: 2187
Study 23468548 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratentorial intracranial artery stenoses and occlusions
Number of subjects: 2187
Study 23468548 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-artery atherosclerosis
Number of subjects: 2187
Study 23468941 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (500 mg/day, up-titrated weekly to a maximum 2,000 mg/day for 16 weeks)
Number of subjects: 371
Study 23468941 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 371
Study 23469326 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 67
Study 23469326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23469326 — intervention group
Group type: EXPERIMENTAL
Intervention: Total WRAADDS
Number of subjects: 67
Study 23471087 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1,200 mg
Number of subjects: 12
Study 23471087 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 23471467 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD current smokers
Number of subjects: 68
Study 23471467 — intervention group
Group type: COMPARATOR
Intervention: COPD ex-smokers
Number of subjects: 68
Study 23471467 — intervention group
Group type: COMPARATOR
Intervention: Healthy smokers
Number of subjects: 68
Study 23471467 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 68
Study 23471754 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index (ANI)
Number of subjects: 25
Study 23471754 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Pleth Index (SPI)
Number of subjects: 25
Study 23471754 — intervention group
Group type: COMPARATOR
Intervention: Bispectral Index (BIS)
Number of subjects: 25
Study 23471754 — intervention group
Group type: COMPARATOR
Intervention: Heart Rate (HR)
Number of subjects: 25
Study 23471754 — intervention group
Group type: COMPARATOR
Intervention: Mean Arterial Pressure (MAP)
Number of subjects: 25
Study 23473415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 23473656 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Well Being Scale (QWB)
Number of subjects: 350
Study 23473656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenert utility score
Number of subjects: 350
Study 23473656 — intervention group
Group type: EXPERIMENTAL
Intervention: Heinrich-Carpenter Quality of Life Scale (QOLS)
Number of subjects: 350
Study 23473656 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive and Negative Syndrome Scale (PANSS)
Number of subjects: 350
Study 23473846 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 6
Study 23474038 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat hydrochloride (50mg, 150mg, and 250mg QOD)
Number of subjects: 9
Study 23474038 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat hydrochloride (150mg or 250mg QOD)
Number of subjects: 9
Study 23474348 — intervention group
Group type: EXPERIMENTAL
Intervention: Farletuzumab with chemotherapy (carboplatin and taxane)
Number of subjects: 54
Study 23474348 — intervention group
Group type: EXPERIMENTAL
Intervention: Farletuzumab with chemotherapy
Number of subjects: 54
Study 23474588 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term glycemia, traditional cardiovascular disease (CVD) risk factors, and ascending aortic stiffness measured with magnetic resonance imaging.
Number of subjects: 879
Study 23474796 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 140
Study 23474796 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic arthroscopy (placebo surgery)
Number of subjects: 140
Study 23474805 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor and granulocyte colony-stimulating factor
Number of subjects: 49
Study 23474805 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-SCT (ASCT)
Number of subjects: 49
Study 23474805 — intervention group
Group type: EXPERIMENTAL
Intervention: Post ASCT
Number of subjects: 49
Study 23474805 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up at 42 months
Number of subjects: 49
Study 23474805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of MDS/AML
Number of subjects: 49
Study 23475281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) and carboplatin (AUC = 6 mg/mL·min) followed by maintenance pemetrexed
Number of subjects: 109
Study 23475281 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance pemetrexed
Number of subjects: 109
Study 23475281 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR wild-type patients
Number of subjects: 109
Study 23475406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR; 50-250 mg b.i.d.)
Number of subjects: 136
Study 23475406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol (PR and IR combined)
Number of subjects: 136
Study 23477369 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized laparoscope-holder (Light Endoscope Robot [LER])
Number of subjects: 16
Study 23477704 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-quantitative pregnancy test at home
Number of subjects: 300
Study 23477704 — intervention group
Group type: EXPERIMENTAL
Intervention: User comprehension survey
Number of subjects: 300
Study 23477833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive soft-tissue sarcoma (group A)
Number of subjects: 162
Study 23477833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive bone sarcoma (group B)
Number of subjects: 162
Study 23477833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-negative bone and soft-tissue sarcoma (group C)
Number of subjects: 162
Study 23478952 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg every 8 hours for 7 days)
Number of subjects: 16
Study 23478952 — intervention group
Group type: COMPARATOR
Intervention: Methadone alone (without telaprevir)
Number of subjects: 16
Study 23479303 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 79
Study 23479303 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight group
Number of subjects: 79
Study 23479303 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 79
Study 23479676 — intervention group
Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia controlled remotely (Montreal)
Number of subjects: 20
Study 23480759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent-high dose oral calcitriol 12 μg/day for 3 days per week for up to 3 months (n=2)
Number of subjects: 9
Study 23480759 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic drugs (5-fluorouracil, Mitomycin C, and Leucovorin) for 3 cycles (n=3)
Number of subjects: 9
Study 23480759 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose calcitriol in combination with chemotherapeutic drugs (n=4)
Number of subjects: 9
Study 23480899 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttrial enrollment campaign 1
Number of subjects: 100
Study 23480899 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttrial enrollment campaign 2
Number of subjects: 100
Study 23480899 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who re-enrolled
Number of subjects: 100
Study 23482470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometer-based objective chromatic perimetry (short-wavelength stimulus, peak 485 nm, light intensity 40 cd/m(2))
Number of subjects: 29
Study 23482470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometer-based objective chromatic perimetry (long-wavelength stimulus, peak 640 nm, light intensity 40 cd/m(2))
Number of subjects: 29
Study 23482470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometer-based objective chromatic perimetry
Number of subjects: 29
Study 23482470 — intervention group
Group type: COMPARATOR
Intervention: Dark-adapted chromatic Goldmann perimetry
Number of subjects: 29
Study 23483536 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 59806
Study 23483536 — intervention group
Group type: COMPARATOR
Intervention: Non-ASA NSAIDs and acetaminophen
Number of subjects: 59806
Study 23483678 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-870,893 (0.1 mg/Kg or 0.2 mg/Kg) combined with carboplatin and paclitaxel
Number of subjects: 32
Study 23483678 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-870,893 (0.2 mg/Kg)
Number of subjects: 32
Study 23484617 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (16 weeks dietary programme with formula products and counselling)
Number of subjects: 192
Study 23484671 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit intervention by certified nurse-midwives
Number of subjects: 130
Study 23484671 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 130
Study 23484829 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline mutations in TP53
Number of subjects: 0
Study 23484829 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study 23484829 — intervention group
Group type: COMPARATOR
Intervention: Family members who are not carriers
Number of subjects: 0
Study 23484911 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat load of 700 kilocalories per m² of body surface area at 83% fat after an 8-h fast.
Number of subjects: 817
Study 23485031 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 461
Study 23485031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of individual components of MetS
Number of subjects: 461
Study 23485031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized variables of MetS
Number of subjects: 461
Study 23485031 — intervention group
Group type: COMPARATOR
Intervention: MetS definitions
Number of subjects: 461
Study 23485794 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month active rehabilitation program consisting of cardiovascular training, knee and hip progressive resistance training, and neuromuscular training.
Number of subjects: 48
Study 23485794 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during the rehabilitation program.
Number of subjects: 48
Study 23487538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib therapy
Number of subjects: 1
Study 23488447 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30) therapy
Number of subjects: 57000
Study 23489023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (240-360 mg twice a day, escalated to 720 mg twice a day)
Number of subjects: 3
Study 23489023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 3
Study 23489259 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAP-BDP level
Number of subjects: 215
Study 23489534 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: Rapid streptokinase
Number of subjects: 182
Study 23489534 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: Slow streptokinase
Number of subjects: 182
Study 23489534 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: High-dose (100 mg) t-PA
Number of subjects: 182
Study 23489534 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV: Half-dose (50 mg) t-PA, slow infusion (6 h) without bolus
Number of subjects: 182
Study 23489534 — intervention group
Group type: EXPERIMENTAL
Intervention: Group V: Low-dose (25 mg) t-PA, slow infusion (6 h) without bolus
Number of subjects: 182
Study 23489534 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 182
Study 23489534 — intervention group
Group type: COMPARATOR
Intervention: Group V vs Groups I-IV
Number of subjects: 182
Study 23489536 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary muscle infarction (PMI) present
Number of subjects: 153
Study 23489536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wall infarction
Number of subjects: 153
Study 23489536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wall infarct size
Number of subjects: 153
Study 23489536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral annular diameter
Number of subjects: 153
Study 23489536 — intervention group
Group type: EXPERIMENTAL
Intervention: LV end-diastolic diameter
Number of subjects: 153
Study 23489536 — intervention group
Group type: COMPARATOR
Intervention: PMI presence
Number of subjects: 153
Study 23489536 — intervention group
Group type: COMPARATOR
Intervention: Angiographic culprit vessel
Number of subjects: 153
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential finger-thumb opposition test
Number of subjects: 0
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid pace walk test
Number of subjects: 0
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelli-Robson contrast sensitivity test
Number of subjects: 0